Bruker (Bruker) Change In Receivables

: $-1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Bruker's change in receivables for the quarter that ended in Dec. 2023 was $12 Mil. It means Bruker's Accounts Receivable declined by $12 Mil from Sep. 2023 to Dec. 2023 .

Bruker's change in receivables for the fiscal year that ended in Dec. 2023 was $-1 Mil. It means Bruker's Accounts Receivable increased by $1 Mil from Dec. 2022 to Dec. 2023 .

Bruker's Accounts Receivable for the quarter that ended in Dec. 2023 was $492 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Bruker's Days Sales Outstanding for the three months ended in Dec. 2023 was 52.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bruker's liquidation value for the three months ended in Dec. 2023 was $-1,495 Mil.

Bruker Change In Receivables Historical Data

The historical data trend for Bruker's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-5.00

40.80

-95.30

-67.90

-0.90

Bruker Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-28.20	8.30	22.20	-42.90	11.50

Bruker Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1 Mil.

Bruker (NAS:BRKR) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Bruker's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	492	/	854.5	*	91
=	52.54

2. In Ben Graham's calculation of liquidation value, Bruker's accounts receivable are only considered to be worth 75% of book value:

Bruker's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	488.3	-	2836.6	+	0.75 * 492	+	0.5 * 968.3
=	-1,495

Bruker Change In Receivables Related Terms

Thank you for viewing the detailed overview of Bruker's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bruker (Bruker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BKD:Germany

Address

40 Manning Road, Billerica, MA, USA, 01821

Website

https://www.bruker.com

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.

Executives

Frank H Laukien	director, 10 percent owner, officer: CEO, President	C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer	director	9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch	officer: Pres. Bruker Nano Inc.	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega	officer: Group President Bruker CALID	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause	officer: Pres. & CEO, Bruker EST	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse	officer: President, BioSpin Group	40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman	officer: Vice President, Corp Contr.	55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139